FDA Adverse Event Reporting System (FAERS)
FOIA Batch Printing Report for Cases

Date - Time: 18-Jul-2023 16:16:52 EDT

Run by: KIA.BAZEMORE@FDA.HHS.GOV

Disclaimer:

Submission of a safety report does not constitute an admission that medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Data provided in the Quarterly Data Extract (QDE) or a FAERS FOIA report are a snapshot of FAERS at a given time. There are several reasons that a case captured in this snapshot can be marked as inactive and not show up in subsequent reports. Manufacturers are allowed to electronically delete reports they submitted if they have a valid reason for deletion. FDA may merge cases that are found to describe a single event, marking one of the duplicate reports as inactive. The data marked as inactive are not lost but may not be available under the original case number.

The cover page will display all Case ID(s) included in the Batch Printing Report and FOIA case report information may include both Electronic Submissions (Esubs) and MedWatch Reports (Non-Esubs).

Cover page Case ID(s) with an asterisk ('*') indicate an invalid status and are not captured in the body of the report.

Cover page Case ID(s) with an asterisk ('**') indicate an failed status and are not captured in the body of the report.

Case ID(s) Printed:

18143068	18340030	20149863	20762799
21159058	22128240		

Total Cases: 6

Total number of Inactive cases: *0

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 18143068

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** **Country:** BE **Event Date:** 04-Aug-2020 **Outcomes:** HO **Application Type:**

FDA Rcvd Date: 21-Aug-2020 **Mfr Rcvd Date:** 14-Aug-2020 **Mfr Control #:** BE-NOVOPROD-745831 **Application #:** 209637

Patient Information:

Age: **Sex:** Male **Weight:**

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic 0.5 mg		6 Mg Milligram(S) / QD	Unknown	6 mg, qd (3 or 4 pen of 0,5mg)		04-Aug-2020	
2	Ozempic 0.5 mg		/	Unknown	UNK	Product used for unknown indication		

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic 0.5 mg		Unknown	Unknown				NOVO NORDISK	
2	Ozempic 0.5 mg		Unknown	Unknown				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0)	ReC
Suicide attempt	
Intentional overdose	
Vomiting	
Nausea	

Event/Problem Narrative:

This serious Spontaneous case from BELGIUM was reported by a Diabetes Nurse Specialist as "suicide attempt by taking 6 mg Ozempic at once(Suicide attempt)" beginning on (b)(6)*****, "Patient has injected 6 mg Ozempic at once(Intentional overdose)" beginning on(b)(6)******, "vomit(Vomiting)" beginning on (b)(6)*****,

Case ID: 18143068

"nauseous(Nauseous)" beginning on(b)(6)******, and concerned a Male patient who was treated with Ozempic 0.5 mg (SEMAGLUTIDE) from unknown start date for "Product used for unknown indication", Medical history was not provided. Treatment included - LITICAN ALIZAPRIDE HYDROCHLORIDE, GLUCOSE The patient's height, weight and body mass index were not reported. Dosage Regimens: Ozempic 0.5 mg: Not Reported to Not Reported, (b)(6)***** to Not Reported; On (b)(6)***** ,Patient made a suicide attempt by Injecting overdose of 6 mg Ozempic at once and is on intensive care (3 or 4 pen of 0,5 mg), and was hospitalised on the same day. The patient had vomited and was nauseous at the emergency. However afterwards, the patient did not present any special gastrointestinal problems. It was reported that patient was given Litican i.v./ under glucose infusion, the glycaemia remained stable. Patient appears to be unfair in his story to the doctors, also with regard to the injected dose. One day it's 6mg and the next patient claims to have only injected 4mg. On an unknown date, patient's glycaemia of the patient is normal, between 100-130 mg/dl. It was reported that the patient would not have had a psychiatric history. The patient was not on psychotropic drugs. The overdose took place in the context of a relational problem, in which the patient said that the patient acted impulsively. Batch Numbers: Ozempic 0.5 mg: ASKU, ASKU Action taken to Ozempic 0.5 mg was Not reported. The outcome for the event "suicide attempt by taking 6 mg Ozempic at once(Suicide attempt)" was Recovered. The outcome for the event "Patient has injected 6 mg Ozempic at once(Intentional overdose)" was Recovered. The outcome for the event "vomit(Vomiting)" was Recovered. The outcome for the event "nauseous(Nauseous)" was Recovered. Since last submission, the fllowing have been updated: -New event, nauseous added -Treatment medications added -Narrative updated accordingly Company comment: 'Suicide attempt' was assessed as unlisted event and 'Nausea', 'Vomiting', were assessed as listed events according to the Novo Nordisk current CCDS on Ozempic. Information on suspect product start date, prior suicidal ideations/attempts, action taken to the drug and relevant investigations were not available for thorough medical evaluation. However overdose of Ozempic could have caused 'nausea' and 'Vomiting'. This single case report is not considered to change the current knowledge of safety profile of Ozempic.

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail
Blood glucose	100-130	milligram per decilitre			N

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 18143068

Reporter Source:

Study report?: No

Sender organization: NOVO NORDISK

503B Compounding Outsourcing Facility?:

Literature Text:

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 18340030

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** **Country:** JP **Event Date:** 15-Sep-2020 **Outcomes:** DE , OT **Application Type:**

FDA Rcvd Date: 10-Dec-2020 **Mfr Rcvd Date:** 14-Oct-2020 **Mfr Control #:** JP-NOVOPROD-754978 **Application #:** 209637

Patient Information:

Age: 54 YR **Sex:** Male **Weight:** 97.4 KG

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic Subcutaneous Injection 0.25mg SD		.25 Mg Milligram(S) / WK	Subcutaneous	0.25 mg, qw	Type 2 diabetes mellitus	27-Aug-2020	15-Sep-2020
2	Tresiba Chu		/	Subcutaneous	UNK	Type 2 diabetes mellitus		

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic Subcutaneous Injection 0.25mg SD	19 Day	Not Applicable	NA				NOVO NORDISK	
2	Tresiba Chu		Not Applicable	NA				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0)	ReC
Suicide attempt	
Hypoglycaemia	
Intentional overdose	

Event/Problem Narrative:

This serious Spontaneous case from JAPAN was reported by a Medical Doctor as "Suicide attempt(Suicide attempt)" beginning on (b)(6)*****, "Hypoglycaemia(Hypoglycaemia)" beginning on (b)(6)*****, "Overdose deliberate self-inflicted(Overdose deliberate self-inflicted)" beginning on -(b)(6)**, and concerned a 54 Years old Male patient who was treated with Tresiba Chu (Insulin Degludec) from unknown start date for "Type 2 diabetes mellitus", , Ozempic

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 18340030

Subcutaneous Injection 0.25mg SD(SEMAGLUTIDE) from 27-AUG-2020 to (b)(6)***** for "Type 2 diabetes mellitus". Patient's height: 176 cm Patient's weight: 97.4 kg Patient's BMI: 31.443. Dosage Regimens: Tresiba Chu: Ozempic Subcutaneous Injection 0.25mg SD : 27-AUG-2020 to (b)(6)*****; Current Condition: Type 2 diabetes mellitus (duration not reported), End stage renal failure, Obesity Procedure: Dialysis. On 27-AUG-2020 patient started on Ozempic 0.25 mg. The drug was administered by a nurse after dialysis at a hospital. On 27-AUG-2020 Blood lactate dehydrogenase was 175(units not reported), Blood alkaline phosphatase was 261(units not reported) and 92(units not reported), Estimated glomerular filtration rate was 5.3(units not reported), Blood glucose was 121(units not reported), Red cell distribution width(RDW-SD) was 49.2(units not reported), Red cell distribution width(RDW-CV) was 15.1(units not reported), Platelet distribution width was 8.7(units not reported), Mean platelet volume(MPV) was 9.2(units not reported), Platelet-large cell ratio(P-LCR) was 17.6(units not reported), C-reactive protein(Blood CPR) was 10.5(units not reported), Glycated albumin was 21.3(units not reported), Brain natriuretic peptide(BNP) was 31.0(units not reported), Corrected Ca level was 8.8(units not reported),FIB-4 index 0.54(units not reported) and Mentzer index was 23(units not reported) On (b)(6)***** (three weeks after the initiation of treatment with Ozempic), the patient had overdose deliberate self-inflicted with Tresiba for suicide attempt. The patient developed hypoglycaemia and died. Batch Number of Tresiba Chu and Ozempic Subcutaneous Injection 0.25mg SD has been requested. Action taken to Tresiba Chu was reported as Not Applicable. Action taken to Ozempic Subcutaneous Injection 0.25mg SD was reported as Not Applicable. The outcome for the event "Suicide attempt(Suicide attempt)" was Unknown. On (b)(6)***** the outcome for the event "Hypoglycaemia(Hypoglycaemia)" was Fatal. The outcome for the event "Overdose deliberate self-inflicted(Overdose deliberate self-inflicted)" was Unknown. On 14-OCT-2020, an Amendment was performed. Since last submission, the following information has been amended: suspect product corrected from Semaglutide B 1.34 mg/mL PDS290 to Semaglutide C DV3372. Company comment: Suicide attempt is assessed as unlisted and Hypoglycemia is assessed as listed according to the Novo Nordisk current CCDS information on Ozempic and Tresiba Chu Information on autopsy report, medical history of any psychiatric disorder ,previous attempts of suicide are not available. However death due to overdose of suspect product and hypoglycemia cannot be denied. As only limited information is available, it is difficult to perform a thorough medical evaluation This single case report is not considered to change the current knowledge of the safety profile of Ozempic and Tresiba Chu

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?
Type 2 diabetes mellitus			
End stage renal disease			
Obesity			
Dialysis			

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail
Adjusted calcium					Y
Blood alkaline phosphatase					Y

Case ID: 18340030

Blood alkaline phosphatase	Y
Blood glucose	Y
Blood lactate dehydrogenase	Y
Brain natriuretic peptide	Y
C-reactive protein	Y
Glomerular filtration rate	Y
Glycated albumin	Y
Mean platelet volume	Y
Platelet distribution width	Y
Platelet-large cell ratio	Y
Red cell distribution width	Y
Red cell distribution width	Y

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event

Reporter Source:

Study report?: No **Sender organization:** NOVO NORDISK **503B Compounding Outsourcing Facility?:**

Literature Text:

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 20149863

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** Y **Country:** FR **Event Date:** **Outcomes:** HO **Application Type:**

FDA Rcvd Date: 06-Dec-2021 **Mfr Rcvd Date:** 24-Nov-2021 **Mfr Control #:** FR-NOVOPROD-871294 **Application #:** 209637

Patient Information:

Age: **Sex:** Female **Weight:**

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic		/	Unknown	UNK	Product used for unknown indication		

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic		Unknown	Unknown				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0) **ReC**

Suicide attempt

Intentional overdose

Event/Problem Narrative:

This serious Spontaneous case from FRANCE was reported by a Physician as "attempted suicide(Attempted suicide)" with an unspecified onset date, "overdosing with Ozempic(Drug overdose deliberate self-inflicted)" with an unspecified onset date, and concerned a Female patient who was treated with Ozempic (SEMAGLUTIDE) from unknown start date for "product used for unknown indication", Patient height, weight and body mass index was not reported. Medical history was not provided. On an unknown date patient attempted suicide by overdosing with Ozempic due to which she was hospitalised. Batch Numbers: Ozempic: Requested. Action taken to Ozempic was reported as Unknown. The outcome for the event "attempted suicide(Attempted suicide)" was Unknown. Company comment: Suicidal attempt is assessed as unlisted event according to the NovoNordisk current company core data sheet (CCDS) on Ozempic The information regarding complete medical history (psychiatric disorders), previous history of suicide attempt, concomitant medications, relevant investigation reports are unavailable which limits the medical assessment of the case This single case report is not considered to change the current knowledge of the safety profile Ozempic The outcome for the event "overdosing with Ozempic(Drug overdose deliberate self-inflicted)" was Not Reported.

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 20149863

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event

Reporter Source:

Study report?: No **Sender organization:** NOVO NORDISK **503B Compounding Outsourcing Facility?:**

Literature Text:

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 20762799

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** N **Country:** AU **Event Date:** **Outcomes:** LT , OT **Application Type:**

FDA Rcvd Date: 28-Apr-2022 **Mfr Rcvd Date:** 18-Apr-2022 **Mfr Control #:** AU-NOVOPROD-911528 **Application #:** 209637

Patient Information:

Age: **Sex:** Female **Weight:**

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic		/	Unknown	UNK	Product used for unknown indication		

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic		Unknown	Unknown				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0)	ReC
Suicide attempt	
Depression	
Product availability issue	

Event/Problem Narrative:

This serious Spontaneous case from AUSTRALIA was reported by a Consumer as "she tried to commit suicide(Suicide attempt)" with an unspecified onset date, "So depressed(Depression)" with an unspecified onset date, "Now we can't get it, she can't keep up with her prescription(product availability issue)" with an unspecified onset date, and concerned a Female patient who was treated with Ozempic (SEMAGLUTIDE) from unknown start date for "Product used for unknown indication", Patient's Height, Weight and Body Mass Index was not reported Current Condition: overweight. It was reported that Ozempic gave us a good start on new lives. Patient has been overweight most of her life; finally found something that works and was helping and nowcan't get it. On an unknown date patient was so depressed she can't keep up with her prescription that she tried to commit suicide. Patient was given antidepressants(unspecified) as treatment drug for Depression Batch Number was requested Action taken to Ozempic was Not reported. The outcome for the event "she tried to commit suicide(Suicide attempt)" was Not Reported. The outcome for the event "So depressed(Depression)" was Not Reported. The outcome for the event "Now we can't get it, she can't keep up

with her prescription(product availability issue)" was Not Reported. Company Comment: “Suicide attempt” and “Depression” are assessed as unlisted according to the Novo Nordisk current CCDS information on Ozempic. Information on medical history including any psychiatric illness, social and family behaviour, previous episodes of suicide attempt would have helped in thorough medical assessment. Patient being overweight is assessed as risk factor for depression and suicide attempt. This single case report is not considered to change the current knowledge of the safety profile of Ozempic.

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?
Overweight			

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event

Reporter Source:

Study report?: No **Sender organization:** NOVO NORDISK **503B Compounding Outsourcing Facility?:**

Literature Text:

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 21159058

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** Y **Country:** CA **Event Date:** 11-Jul-2022 **Outcomes:** OT **Application Type:**

FDA Rcvd Date: 02-Aug-2022 **Mfr Rcvd Date:** 22-Jul-2022 **Mfr Control #:** CA-NOVOPROD-943524 **Application #:** 209637

Patient Information:

Age: **Sex:** Female **Weight:**

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic		/		UNK	Type 2 diabetes mellitus	24-May-2022	

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic	48 Day	NA	NA				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0) **ReC**

Suicide attempt

Depression

Event/Problem Narrative:

This serious Spontaneous case from CANADA was reported by a Endocrinologist as "Suicidal attempt(Attempted suicide)" beginning on 11-JUL-2022, "Started to feel depressed(Depressed state)" with an unspecified onset date, and concerned a Female patient who was treated with Ozempic (SEMAGLUTIDE) from 24-MAY-2022 for "Type 2 diabetes mellitus", Patient's height, weight and body mass index were not reported. Dosage Regimens: Ozempic: 24-MAY-2022 to Not Reported; Current Condition: Type 2 diabetes mellitus (duration not reported), Fibromyalgia. Concomitant products included - METFORMIN, GLICLAZIDE , FLICK AZURE (non-codable) On an unknown date, patient started to feel depressed after taking Ozempic. On (b)(6)*****, the patient did Suicidal attempt, but survived unscathed (took all her meds at once). The patient was seen in ER at Hospital. The patient had been off all antihyperglycemics. Batch Number for Ozempic not reported. Action taken to Ozempic was reported as Product discontinued. The outcome for the event "Suicidal attempt(Attempted suicide)" was Not Reported. The outcome for the event "Started to feel depressed(Depressed state)" was Not Reported. No further information available. Company comment: 'Suicide attempt' and 'Depression' are assessed as unlisted events according to the Novo Nordisk current CCDS on Ozempic. Information regarding concomitant medications (any

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 21159058

illicit drug use) complete medical history (psychological disorder, social disturbances, stress, etc.) and relevant investigation report is unavailable which limits the medical assessment of the case. This single case report is not considered to change the current knowledge of the safety profile of Ozempic.

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?
Type 2 diabetes mellitus			Yes
Fibromyalgia			Yes

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event
1	METFORMIN	/		UNK	Product used for unknown indication			
2	GLICLAZIDE	/		UNK	Product used for unknown indication			

Reporter Source:

Study report?: No **Sender organization:** NOVO NORDISK **503B Compounding Outsourcing Facility?:**

Literature Text:

FDA - Adverse Event Reporting System (FAERS)
FOIA Case Report Information

Case ID: 22128240

Case Information:

Case Type : Expedited (15-Day) **eSub:** Y **HP:** Y **Country:** LB **Event Date:** **Outcomes:** HO **Application Type:**

FDA Rcvd Date: 03-Apr-2023 **Mfr Rcvd Date:** 23-Mar-2023 **Mfr Control #:** LB-NOVOPROD-1038887 **Application #:** 209637

Patient Information:

Age: **Sex:** Female **Weight:**

Suspect Products:

#	Product Name:	Compounded Drug ?	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date
1	Ozempic 1.0 mg		/		UNK	Product used for unknown indication		

#	Product Name:	Interval 1st Dose to Event	DeC	ReC	Lot#	Exp Date	NDC #	MFR/Labeler	OTC
1	Ozempic 1.0 mg		Unknown	NA				NOVO NORDISK	

Event Information:

Preferred Term (MedDRA Version: v.26.0) **ReC**

Suicide attempt

Intentional overdose

Event/Problem Narrative:

This serious Spontaneous case from LEBANON was reported by a Physician as "attempted to commit suicide(Suicide attempt)" with an unspecified onset date, "taking 1 full pen of Ozempic 1mg in one day(Intentional overdose)" with an unspecified onset date, and concerned a Female patient (age not reported) who was treated with Ozempic 1.0 mg (SEMAGLUTIDE) from unknown start date for "Drug use for unknown indication". Patient's height weight and body mass index were not reported Medical history was not provided. Concomitant products included - Xanax(Alprazolam), Stilnox(Zolpidem Tartrate) On an unspecified date, the patient tried to commit suicide by taking 1 full pen of Ozempic 1mg in one day, in addition to Xanax and Stilnox. The patient was hospitalized to the ER. The blood tests were normal. (Test name, values and units were not reported). After that left the hospital. Batch Numbers: Ozempic 1.0 mg: not reported. Action taken to Ozempic 1.0 mg was Not reported. The outcome for the event "attempted to commit suicide(Suicide attempt)" was Not Reported. The outcome for the event "taking 1 full pen of Ozempic 1mg in one day(Intentional overdose)" was Not Reported. No further information available. Since last submission case updated with the following information: New lab data has been added NFI updated Narrative updated accordingly. Company comment: Suicide attempt is assessed as unlisted event and

Case ID: 22128240

intentional overdose is assessed as listed event according to NovoNordisk current reference safety information on Ozempic. Information on demographic details of the patient, history of any risk factors like psychiatric disorders, psychological disorders, anxiety, depression, social and family behavior, relevant medical history, relevant clinical and investigation results, action taken with the suspect, event onset dates with outcome, exposure details of the suspect are unavailable for thorough medical assessment. This single case report is not considered to change the current knowledge of the safety profile of Ozempic.

Relevant Medical History:

Disease/Surgical Procedure	Start Date	End Date	Continuing?

Medical History Product(s)	Start Date	End Date	Indications	Events

Relevant Laboratory Data:

Test Name	Result	Unit	Normal Low Range	Normal High Range	Info Avail
BLOOD TEST					Y

Concomitant Products:

#	Product Name:	Dose/Frequency	Route	Dosage Text	Indication(s)	Start Date	End Date	Interval 1st Dose to Event
1	XANAX	/		UNK	Product used for unknown indication			
2	STILNOX	/		UNK	Product used for unknown indication			

Reporter Source:

Study report?: No **Sender organization:** NOVO NORDISK **503B Compounding Outsourcing Facility?:**

Literature Text: